Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
9
×
life sciences
national blog main
san diego blog main
9
×
national top stories
san diego top stories
boston blog main
boston top stories
new york blog main
new york top stories
san francisco blog main
san francisco top stories
biotech
boulder/denver blog main
texas blog main
texas top stories
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
drugs
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
wisconsin blog main
wisconsin top stories
akcea therapeutics
alnylam pharmaceuticals
boston
hereditary transthyretin amyloidosis
indiana blog main
indiana top stories
inotersen
patisiran
tafamidis
cancer
ceo
commissioner
What
medicine
9
×
fda
drug
alnylam
approved
bio
cancer
cells
loss
patients
rna
rnai
roundup
san
technology
time
uses
afternoon
ago
alnylam’s
antonio
approve
approves
awaits
big
biological
biopharma
bosley's
bosley’s
bridge
bucks
car
cas
celgene
ceo
cleared
clinical
colleagues
comes
company
Language
unset
Current search:
medicine
×
" san diego blog main "
×
fda
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
San Antonio Seeks to Be Known as Silicon Valley of Military Medicine
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
6 years ago
Histogen Treatment for Female Hair Loss Cleared for Clinical Testing